-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune ...
Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback